Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer

• Published in: Nature cancer Vol. 4; no. 10; p. 1491
• Main Authors: Miller, Katelyn D, O'Connor, Seamus, Pniewski, Katherine A, Kannan, Toshitha, Acosta, Reyes, Mirji, Gauri, Papp, Sara, Hulse, Michael, Mukha, Dzmitry, Hlavaty, Sabina I, Salcido, Kelsey N, Bertolazzi, Fabrizio, Srikanth, Yellamelli V V, Zhao, Steven, Wellen, Kathryn E, Shinde, Rahul S, Claiborne, Daniel T, Kossenkov, Andrew, Salvino, Joseph M, Schug, Zachary T
• Format: Journal Article
• Language: English
• Published: England 01.10.2023
• Subjects: Acetates - metabolism; Acetates - pharmacology; Acetates - therapeutic use; Acetyl Coenzyme A - metabolism; Breast Neoplasms - drug therapy; Cell Line, Tumor; Female; Humans; Immunologic Factors; T-Lymphocytes - metabolism; Tumor Microenvironment
• ISSN: 2662-1347
• DOI: 10.1038/s43018-023-00636-6

Acetate metabolism is an important metabolic pathway in many cancers and is controlled by acetyl-CoA synthetase 2 (ACSS2), an enzyme that catalyzes the conversion of acetate to acetyl-CoA. While the metabolic role of ACSS2 in cancer is well described, the consequences of blocking tumor acetate metabolism on the tumor microenvironment and antitumor immunity are unknown. We demonstrate that blocking ACSS2, switches cancer cells from acetate consumers to producers of acetate thereby freeing acetate for tumor-infiltrating lymphocytes to use as a fuel source. We show that acetate supplementation metabolically bolsters T-cell effector functions and proliferation. Targeting ACSS2 with CRISPR-Cas9 guides or a small-molecule inhibitor promotes an antitumor immune response and enhances the efficacy of chemotherapy in preclinical breast cancer models. We propose a paradigm for targeting acetate metabolism in cancer in which inhibition of ACSS2 dually acts to impair tumor cell metabolism and potentiate antitumor immunity.